HCW Biologics receives Nasdaq delisting notice over equity non-compliance

HCW Biologics Inc.

Received notice Aug 19, 2025 that as of June 30, 2025 it is non-compliant with Nasdaq Equity Rule 5550(b)(1).
Trading suspension set for Aug 28, 2025 unless hearing requested by Aug 26; company plans to request stay.
Subject to Panel Monitor through June 23, 2026; no compliance plan opportunity if non-compliant again.
Company considering all options but no assurance the Panel will grant continued listing.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.